文献速递角膜与眼表疾病

棘阿米巴角膜炎治疗:227例中不同抗阿米巴治疗的治愈时间与视力结局分析

Acanthamoeba keratitis therapy: time to cure and visual outcome analysis for different antiamoebic therapies in 227 cases.
PubMed 文献 · Br J Ophthalmol · 2019-08-10

该回顾性队列研究纳入1991年7月25日至2012年8月10日间发生的227例棘阿米巴角膜炎患者,分析不同局部抗阿米巴治疗(AAT)的结局。按基线AAT分析,12个月药物治疗治愈率为60.79%(138/227),不良结局为49.34%(112/227),各治疗间无显著差异;按互斥AAT分组分析,PHMB单药治疗结局最佳,但存在偏倚需谨慎解读。总体治愈率94.27%(214/227),中位治愈时间5个月(IQR 3.25-9.00个月)。

要点

  • 按基线AAT分析,12个月药物治疗治愈率为60.79%(138/227),不良结局为49.34%(112/227),各治疗间无显著差异。
  • 按互斥AAT分组分析,PHMB单药治疗提供最佳结局,但存在偏倚需谨慎解读。
  • 总体治愈率94.27%(214/227),中位治愈时间5个月(IQR 3.25-9.00个月),范围1-26.24个月。

核心结论

  • 0.02% PHMB单药治疗作为AK初始治疗与双胍类+二脒类联合治疗同样有效。
  • 氯己定单药治疗病例太少无法比较。
  • 本结局数据是现有最详细的。

研究设计与样本

  • 回顾性队列研究,纳入1991年7月25日至2012年8月10日间发生的227例棘阿米巴角膜炎患者。
  • 纳入标准要求有完整的AAT治疗记录,主要结局为12个月药物治疗治愈率,次要结局为Snellen视力≤6/24和/或手术干预。
  • 采用多变量回归控制基線疾病特征差异,其他结局采用未校正分析。
  • 按基线AAT和互斥AAT(患者暴露于每组所有药物且无其他药物一段时间)两种方式分类分析。
  • AAT类别包括PHMB单药、PHMB+二脒类、PHMB+氯己定+二脒类、二脒类单药和其他AAT。

主要发现

  • 按基线AAT分析,12个月药物治疗治愈率为60.79%(138/227),不良结局为49.34%(112/227),各治疗间无显著差异。
  • 按互斥AAT分组分析,PHMB单药治疗提供最佳结局,但这些发现存在偏倚需谨慎解读。
  • 214例结局已解决者的总体治愈率为94.27%(214/227),中位治愈时间5个月(IQR 3.25-9.00个月),范围1-26.24个月。

临床怎么用

  • 作者结论认为0.02% PHMB单药治疗作为AK初始治疗与双胍类+二脒类联合治疗同样有效。
  • 作者指出氯己定单药治疗病例太少无法比较。

局限性

  • 这些发现存在偏倚需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To test the hypothesis that Acanthamoeba keratitis (AK) outcomes differ for different topical antiamoebic therapies (AAT) and to provide the detailed patient outcome data. METHODS: A retrospective cohort study of 227 patients developing AK between 25 July 1991 and 10 August 2012. Inclusion criteria required a complete record of AAT treatment for both the primary outcome of a medical cure rate at 12 months and the secondary outcome of Snellen visual acuity ≤6/24 and/or surgical intervention. Analysis used multivariable regression to control for differences in baseline disease characteristics for both primary and secondary outcomes with unadjusted analyses for other outcomes. Subjects were categorised for analysis both by the AAT used at baseline and also by mutually exclusive AAT (patients exposed to all the drugs in each group, and no others, for some period). AAT categories were PHMB monotherapy, PHMB+diamidine, PHMB+chlorhexidine+diamidine, diamidine monotherapy and other AAT. RESULTS: Analysis by baseline AAT showed no notable difference between treatments for both a medical cure at 12 months in 60.79% (138/227) or for a poor outcome in 49.34% (112/227). When AATs were analysed by mutually exclusive groups, PHMB monotherapy provided the best outcomes. These findings are subject to bias requiring careful interpretation. Overall cure rates for the 214 subjects with resolved outcomes were 94.27% (214/227), median time to cure 5 months (IQR 3.25-9.00 months) and range 1-26.24 months. CONCLUSION: PHMB 0.02% monotherapy for the initial treatment of AK is as effective as biguanide+diamidine combination therapy. Chlorhexidine monotherapy was too infrequent for comparison. The outcome data are the most detailed available.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Papa V, Rama P, Radford C, et al. Acanthamoeba keratitis therapy: time to cure and visual outcome analysis for different antiamoebic therapies in 227 cases. Br J Ophthalmol. 2019. PMID: 31401556. doi:10.1136/bjophthalmol-2019-314485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。